HRP20201644T1 - Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba - Google Patents
Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba Download PDFInfo
- Publication number
- HRP20201644T1 HRP20201644T1 HRP20201644TT HRP20201644T HRP20201644T1 HR P20201644 T1 HRP20201644 T1 HR P20201644T1 HR P20201644T T HRP20201644T T HR P20201644TT HR P20201644 T HRP20201644 T HR P20201644T HR P20201644 T1 HRP20201644 T1 HR P20201644T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- crystalline
- crystalline form
- crystal form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610082029.8A CN107043379A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| EP17747004.4A EP3412672B1 (en) | 2016-02-05 | 2017-02-04 | Crystal form a of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl) benzyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine as tlr7 agonist, preparation method and use thereof |
| PCT/CN2017/072891 WO2017133684A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的晶型a、其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201644T1 true HRP20201644T1 (hr) | 2020-12-25 |
Family
ID=59499348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201644TT HRP20201644T1 (hr) | 2016-02-05 | 2017-02-04 | Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10442811B2 (2) |
| EP (1) | EP3412672B1 (2) |
| JP (1) | JP6889171B2 (2) |
| KR (1) | KR102393280B1 (2) |
| CN (2) | CN107043379A (2) |
| AR (1) | AR107548A1 (2) |
| AU (1) | AU2017215801B2 (2) |
| CA (1) | CA3013518C (2) |
| CL (1) | CL2018002092A1 (2) |
| DK (1) | DK3412672T3 (2) |
| EA (1) | EA035951B1 (2) |
| ES (1) | ES2830443T3 (2) |
| HR (1) | HRP20201644T1 (2) |
| HU (1) | HUE051399T2 (2) |
| IL (1) | IL260968B (2) |
| LT (1) | LT3412672T (2) |
| MX (1) | MX374297B (2) |
| NZ (1) | NZ744884A (2) |
| PH (1) | PH12018501643A1 (2) |
| PL (1) | PL3412672T3 (2) |
| PT (1) | PT3412672T (2) |
| SG (1) | SG11201806683UA (2) |
| SI (1) | SI3412672T1 (2) |
| TW (1) | TWI754629B (2) |
| UA (1) | UA121161C2 (2) |
| WO (1) | WO2017133684A1 (2) |
| ZA (1) | ZA201805186B (2) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3368092B9 (en) | 2015-10-29 | 2020-07-29 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| AU2019272478B2 (en) * | 2018-05-25 | 2024-06-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR7 agonist and pharmaceutical combination thereof for treating lung cancer |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| TWI908718B (zh) * | 2019-03-15 | 2025-12-21 | 大陸商正大天晴藥業集團股份有限公司 | 類鐸受體促效劑給藥方案 |
| JP2022530444A (ja) * | 2019-04-23 | 2022-06-29 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｔｌｒ７アゴニストを含む固体医薬組成物 |
| CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| US20230277525A1 (en) | 2020-08-04 | 2023-09-07 | Progeneer Inc | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
| JP7690221B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
| US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| CN119431359A (zh) * | 2023-07-28 | 2025-02-14 | 苏州申拓医药科技有限公司 | 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| CN101304748A (zh) * | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
| RS53347B (sr) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| WO2012106522A2 (en) * | 2011-02-04 | 2012-08-09 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| EP2800569B1 (en) | 2012-01-05 | 2018-07-25 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| DK2906563T3 (en) | 2012-10-10 | 2018-06-06 | Janssen Sciences Ireland Uc | PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES |
| BR112015011439A2 (pt) | 2012-11-20 | 2017-07-11 | Glaxosmithkline Llc | composto, composição farmacêutica, composição de vacina, e, uso de um composto |
| EA028480B1 (ru) * | 2012-11-20 | 2017-11-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Новые соединения |
| AU2013348217B2 (en) * | 2012-11-20 | 2016-10-06 | Glaxosmithkline Llc | Novel compounds |
| PL3137470T3 (pl) | 2014-05-01 | 2021-10-11 | Novartis Ag | Związki i kompozycje jako agonisty receptora toll-like 7 |
| HRP20210927T1 (hr) * | 2014-08-15 | 2021-09-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Spojevi pirolopirimidina koje se koriste kao agonist tlr7 |
| CN105367576A (zh) | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
-
2016
- 2016-02-05 CN CN201610082029.8A patent/CN107043379A/zh active Pending
-
2017
- 2017-02-03 TW TW106103695A patent/TWI754629B/zh active
- 2017-02-04 CN CN201780009747.5A patent/CN108602831B9/zh active Active
- 2017-02-04 UA UAA201809129A patent/UA121161C2/uk unknown
- 2017-02-04 KR KR1020187024627A patent/KR102393280B1/ko active Active
- 2017-02-04 MX MX2018009501A patent/MX374297B/es active IP Right Grant
- 2017-02-04 SG SG11201806683UA patent/SG11201806683UA/en unknown
- 2017-02-04 DK DK17747004.4T patent/DK3412672T3/da active
- 2017-02-04 ES ES17747004T patent/ES2830443T3/es active Active
- 2017-02-04 US US16/075,297 patent/US10442811B2/en active Active
- 2017-02-04 PT PT177470044T patent/PT3412672T/pt unknown
- 2017-02-04 EP EP17747004.4A patent/EP3412672B1/en active Active
- 2017-02-04 NZ NZ744884A patent/NZ744884A/en unknown
- 2017-02-04 CA CA3013518A patent/CA3013518C/en active Active
- 2017-02-04 LT LTEP17747004.4T patent/LT3412672T/lt unknown
- 2017-02-04 WO PCT/CN2017/072891 patent/WO2017133684A1/zh not_active Ceased
- 2017-02-04 AU AU2017215801A patent/AU2017215801B2/en active Active
- 2017-02-04 PL PL17747004T patent/PL3412672T3/pl unknown
- 2017-02-04 JP JP2018540799A patent/JP6889171B2/ja active Active
- 2017-02-04 EA EA201891768A patent/EA035951B1/ru not_active IP Right Cessation
- 2017-02-04 HR HRP20201644TT patent/HRP20201644T1/hr unknown
- 2017-02-04 HU HUE17747004A patent/HUE051399T2/hu unknown
- 2017-02-04 SI SI201730461T patent/SI3412672T1/sl unknown
- 2017-02-06 AR ARP170100297A patent/AR107548A1/es not_active Application Discontinuation
-
2018
- 2018-08-01 ZA ZA2018/05186A patent/ZA201805186B/en unknown
- 2018-08-02 PH PH12018501643A patent/PH12018501643A1/en unknown
- 2018-08-02 IL IL260968A patent/IL260968B/en unknown
- 2018-08-03 CL CL2018002092A patent/CL2018002092A1/es unknown
-
2019
- 2019-09-25 US US16/582,575 patent/US10947245B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201644T1 (hr) | Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba | |
| HRP20201275T1 (hr) | Kristalni oblik derivata benzimidazola i postupak njegove proizvodnje | |
| HRP20160208T4 (hr) | Polimorfi dasatiniba i postupak za njihovu pripremu | |
| HRP20141137T1 (hr) | Polimorfni oblici macrocikliäśkog inhibitora hcv | |
| RU2018145948A (ru) | Кристалл пирролопиримидина для получения jak-ингибитора | |
| BRPI0807319B1 (pt) | Base de minociclina cristalina forma 1, processo para preparar base de minociclina cristalina forma i, base de minociclina cristalina forma ii, processo para preparar base de minociclina cristalina forma ii, base de minociclina cristalina forma iii e processo para preparar base de minociclina cristalina forma iii | |
| HRP20240304T1 (hr) | Soli valbenazin dihidroklorida i njihovi polimorfi | |
| HRP20160168T1 (hr) | Kristalne forme makrolida i njihova uporaba | |
| JP2019505533A5 (2) | ||
| EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
| JP2015522644A5 (2) | ||
| CN101139325A (zh) | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法 | |
| AU2006301708A1 (en) | Glycyrrhetinic acid-30-amide derivatives and the uses thereof | |
| JP2022535870A (ja) | Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途 | |
| HRP20151343T1 (hr) | Agomelatin hidrobromid hidrat i njegova priprema | |
| JP2022060192A5 (2) | ||
| CN104086544B (zh) | 阿哌沙班一水合物及其制备方法和药物组合物 | |
| ME02509B (me) | Proces za proizvodnju metansulfonatnih soli ralfinamida ili njihovih r-enantiomera | |
| WO2018185711A1 (en) | Solvates of eluxadoline | |
| CZ305213B6 (cs) | Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy | |
| TWI824626B (zh) | Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型 | |
| JP2018518515A (ja) | フェニルアミノピリミジン化合物またはその塩の多形物 | |
| JP2016533361A (ja) | ピラゾロピリジン化合物の固体形態 | |
| CN103709140A (zh) | 泮托拉唑钠的晶体及其制备方法 | |
| JP6072908B2 (ja) | 重水素化ω―ジメチル尿素又はその塩の多形物 |